-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Inhaled preparations are a common method of administration for patients with respiratory diseases.
Due to their advantages of convenient administration, quick onset of action, and avoidance of first-pass liver effects, they have been recommended by domestic and foreign guidelines as the preferred treatment for asthma and COPD
.
According to data, the global inhalation preparation market maintained a growth rate of 5.
4% from 2013 to 2019, and the global scale has increased to 48 billion U.
S.
dollars in 2019
.
In recent years, with the increase in the incidence of respiratory diseases in China and the support of relevant national policies, the domestic inhalation market is also continuing to expand
.
In particular, it is worth mentioning that with the release of the "Guidelines for the Bioequivalence Research of Oral Inhalation Preparations Generic Drugs" by the Center for Drug Evaluation (CDE) of the National Medical Products Administration in December 2020, the domestic inhalation preparation industry has begun to welcome Here comes the outbreak period and the accelerated era of domestic substitution
.
According to data, in recent years, the inhalation drug market in China's public medical institutions has been expanding year by year, and the annual growth rate has remained at double digits.
It exceeded the 20 billion mark for the first time in 2018, and the scale reached 236.
8 in 2019.
Billion yuan, an increase of 10.
51% year-on-year
.
At present, in the face of the inhalation preparation market with huge domestic development space, many domestic pharmaceutical companies are vying to lay out
.
For example, in the recent announcement by Borui Pharmaceuticals to adjust its convertible corporate bond plan, it said that the total amount of funds raised from the proposed issuance of convertible corporate bonds will not exceed RMB 465 million.
After deducting the issuance costs, the funds raised will be used for the company's inhalants and other chemical pharmaceutical preparations.
Construction of a new project (phase one) of the production base and biomedical R&D center
.
In addition to the above-mentioned companies, domestic companies that are actively deploying inhalation preparations include Joincare, Chia Tai Tianqing, Hengrui Pharmaceuticals and Changfeng Pharmaceuticals
.
Among them, Joincare insists on breakthroughs with features such as respiratory drug delivery technology platforms and innovative R&D technology platforms, focusing on respiratory and other fields
.
Currently, it has 4 inhalation preparation products on the market.
Among them, budesonide suspension for inhalation, compound ipratropium bromide solution for inhalation, and ipratropium bromide solution for inhalation were successfully selected in the fifth batch of national centralized procurement
.
It is worth mentioning that in fact, many companies have very rich R&D pipelines, and while covering a variety of dosage forms, they are gradually accelerating the transition from "imitation-based" to "combination of imitation and innovation
.
" Influenced by the accelerated innovation of more and more companies, the domestic inhalation market has actually been approved for listing many new products this year, such as the ipratropium bromide solution for inhalation of Wuhan Xianlu Pharmaceutical Technology, and Renhe Lijian Pharmaceutical ( Tianjin) inhalation solution of compound ipratropium bromide, inhaled Zhejiang Ferrer hi Pharmaceutical solution by ipratropium bromide and compound suction ipratropium bromide solution or the like
.
In this regard, the industry believes that although in the past restricted by barriers such as preparation technology and patents, foreign brands in the domestic inhalation market as a whole still accounted for a relatively large proportion, but with the continuous rise of domestic companies, domestic brands have already "survived.
" The trend
.
In the future, as domestic products continue to be approved for the market and enter centralized procurement, original research drugs may be impacted, and the market structure of tens of billions of inhalants will also change
.
At the same time, competition among domestic generic drugs is expected to become increasingly fierce
.
Due to their advantages of convenient administration, quick onset of action, and avoidance of first-pass liver effects, they have been recommended by domestic and foreign guidelines as the preferred treatment for asthma and COPD
.
According to data, the global inhalation preparation market maintained a growth rate of 5.
4% from 2013 to 2019, and the global scale has increased to 48 billion U.
S.
dollars in 2019
.
In recent years, with the increase in the incidence of respiratory diseases in China and the support of relevant national policies, the domestic inhalation market is also continuing to expand
.
In particular, it is worth mentioning that with the release of the "Guidelines for the Bioequivalence Research of Oral Inhalation Preparations Generic Drugs" by the Center for Drug Evaluation (CDE) of the National Medical Products Administration in December 2020, the domestic inhalation preparation industry has begun to welcome Here comes the outbreak period and the accelerated era of domestic substitution
.
According to data, in recent years, the inhalation drug market in China's public medical institutions has been expanding year by year, and the annual growth rate has remained at double digits.
It exceeded the 20 billion mark for the first time in 2018, and the scale reached 236.
8 in 2019.
Billion yuan, an increase of 10.
51% year-on-year
.
At present, in the face of the inhalation preparation market with huge domestic development space, many domestic pharmaceutical companies are vying to lay out
.
For example, in the recent announcement by Borui Pharmaceuticals to adjust its convertible corporate bond plan, it said that the total amount of funds raised from the proposed issuance of convertible corporate bonds will not exceed RMB 465 million.
After deducting the issuance costs, the funds raised will be used for the company's inhalants and other chemical pharmaceutical preparations.
Construction of a new project (phase one) of the production base and biomedical R&D center
.
In addition to the above-mentioned companies, domestic companies that are actively deploying inhalation preparations include Joincare, Chia Tai Tianqing, Hengrui Pharmaceuticals and Changfeng Pharmaceuticals
.
Among them, Joincare insists on breakthroughs with features such as respiratory drug delivery technology platforms and innovative R&D technology platforms, focusing on respiratory and other fields
.
Currently, it has 4 inhalation preparation products on the market.
Among them, budesonide suspension for inhalation, compound ipratropium bromide solution for inhalation, and ipratropium bromide solution for inhalation were successfully selected in the fifth batch of national centralized procurement
.
It is worth mentioning that in fact, many companies have very rich R&D pipelines, and while covering a variety of dosage forms, they are gradually accelerating the transition from "imitation-based" to "combination of imitation and innovation
.
" Influenced by the accelerated innovation of more and more companies, the domestic inhalation market has actually been approved for listing many new products this year, such as the ipratropium bromide solution for inhalation of Wuhan Xianlu Pharmaceutical Technology, and Renhe Lijian Pharmaceutical ( Tianjin) inhalation solution of compound ipratropium bromide, inhaled Zhejiang Ferrer hi Pharmaceutical solution by ipratropium bromide and compound suction ipratropium bromide solution or the like
.
In this regard, the industry believes that although in the past restricted by barriers such as preparation technology and patents, foreign brands in the domestic inhalation market as a whole still accounted for a relatively large proportion, but with the continuous rise of domestic companies, domestic brands have already "survived.
" The trend
.
In the future, as domestic products continue to be approved for the market and enter centralized procurement, original research drugs may be impacted, and the market structure of tens of billions of inhalants will also change
.
At the same time, competition among domestic generic drugs is expected to become increasingly fierce
.
